Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder

References

• Burns A, Jacoby R, Levy R. Psychiatric phenomena in alzheimer’s disease. Br J Psychiatry. 1990;157(81–6):92–94.
   Google Scholar
• Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European alzheimer disease consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457–463.
   PubMed Web of Science ®Google Scholar
• Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev. 2002;21:CD003944.
   Google Scholar
• Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66–71.
   PubMed Web of Science ®Google Scholar
• Bassiony MM, Warren A, Rosenblatt A, et al. The relationship between delusions and depression in alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17:549–556.
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Capurso C, et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry. 2010;18:98–116.
   PubMed Web of Science ®Google Scholar
• Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125–128.
   PubMed Web of Science ®Google Scholar
• Charney DS, Reynolds CF III, Lewis L, et al. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry. 2003;60:664–672.
   PubMed Web of Science ®Google Scholar
• Lozupone M, Veneziani F, Lofano L, et al. Educational level influenced the gold standard diagnosis of late-life depression in the greatage study. Eur Psychiatry. 2017;41S:S173.
   Google Scholar
• Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530–538.
   PubMed Web of Science ®Google Scholar
• Ganguli M, Du Y, Dodge HH, et al. Depressive symptoms and cognitivedecline in late life: a prospective epidemiological study. Arch Gen Psychiatry. 2006;63:153–160.
   PubMed Web of Science ®Google Scholar
• Geerlings MI, Schoevers RA, Beekman AT, et al. Depression and risk of cognitive decline and alzheimer’s disease: results of two prospective community-based studies in the Netherlands. Br J Psychiatry. 2000;176:568–575.
   PubMed Web of Science ®Google Scholar
• Singh-Manoux A, Dugravot A, Fournier A, et al. Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. JAMA Psychiatry. 2017;74:712–718.
   PubMed Web of Science ®Google Scholar
• Dekker AD, Strydom A, Coppus AM, et al. Behavioural and psychological symptoms of dementia in down syndrome: early indicators of clinical alzheimer’s disease? Cortex. 2015;73:36–61.
   PubMed Web of Science ®Google Scholar
• Zweig RM, Ross CA, Hedreen JC. The neuropathology of aminergic nuclei in alzheimer’s disease. Ann Neurol. 1988;24:233–242.
   PubMed Web of Science ®Google Scholar
• Zweig RM, Ross CA, Hedreen JC, et al. Neuropathology of aminergic nuclei in alzheimer disease. Prog Clin Biol Res. 1989;317:353–365.
   PubMedGoogle Scholar
• Forstl H, Burns A, Luthert P. Clinical and neuropathological correlates of depression in alzheimer’s disease. Psychol Med. 1992;22:877–884.
   PubMed Web of Science ®Google Scholar
• Sierksma AS, Van Den Hove DL, Steinbusch HW, et al. Major depression, cognitive dysfunction and alzheimer’s disease: is there a link? Eur J Pharmacol. 2010;626:72–82.
   PubMed Web of Science ®Google Scholar
• Ferrero H, Solas M, Francis PT, et al. Serotonin 5-HT6 receptor antagonists in alzheimer’s disease: therapeutic rationale and current development status. CNS Drugs. 2017;31:19–32.
   PubMed Web of Science ®Google Scholar
• Khundakar AA, Aj T. Neuropathology of depression in alzheimer’s disease: current knowledge and the potential for new treatments. J Alzheimers Dis. 2015;44:27–41.
   PubMed Web of Science ®Google Scholar
• Onder G, Penninx BWJH, Cesari M, et al. Anemia is associated with depression in older adults: results from the inchianti study. J Gerontol A Biol Sci Med Sci. 2005;60:1168–1172.
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Keltz MA, Smith JS. Role of citalopram in the treatment of agitation in alzheimer’s disease. Neurodegener Dis Manag. 2014;4:345–349.
   PubMedGoogle Scholar
• Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-b levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108:14968–14973.
   PubMed Web of Science ®Google Scholar
• Shen F, Smith JA, Chang R, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69–79.
   PubMed Web of Science ®Google Scholar
• Fisher JR, Wallace CE, Tripoli DL, et al. Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo. Mol Neurodegener. 2016;11:45.
   PubMed Web of Science ®Google Scholar
• Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236re4.
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Rogers J. Inflammation in alzheimer disease: a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2:a006346.
   PubMed Web of Science ®Google Scholar
• Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology. 2013;67:304–317.
   PubMed Web of Science ®Google Scholar
• Taler M, Gil-Ad I, Korob I, et al. The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18:117–122.
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang J, Wang H, et al. Regulation of astrocyte pathology by fluoxetine prevents the deterioration of alzheimer phenotypes in an APP/PS1 mouse model. Glia. 2016;64:240–254.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Xu H, et al. Fluoxetine improves behavioral performance by suppressing the production of soluble beta-amyloid in APP/PS1 mice. Curr Alzheimer Res. 2014;11:672–680.
   PubMed Web of Science ®Google Scholar
• Wang DD, Li J, Yu LP, et al. Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in alzheimer’s disease associated mice. J Integr Neurosci. 2016;15:247–260.
   PubMed Web of Science ®Google Scholar
• Caraci F, Tascedda F, Merlo S, et al. Fluoxetine prevents abeta1-42-induced toxicity via a paracrine signaling mediated by transforming-growth-factor-beta1. Front Pharmacol. 2016;7(25):389.
   PubMed Web of Science ®Google Scholar
• Caraci F, Spampinato SF, Morgese MG, et al. Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target. Pharmacol Res. 2018;S1043-6618(17):31600–31606. pii.
   Google Scholar
• Then CK, Liu KH, Liao MH, et al. Antidepressants, sertraline and paroxetine, increase calcium influx and inducemitochondrial damage-mediated apoptosis of astrocytes. Oncotarget. 2017;8:115490–115502.
   PubMedGoogle Scholar
• Gong R, Park CS, Abbassi NR, et al. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem. 2006;281:18802–18815.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964.
   PubMed Web of Science ®Google Scholar
• Hoeffer CA. Klann E mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33:67–75.
   PubMed Web of Science ®Google Scholar
• Patel K, Abdool PS, Rajji TK, et al. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opin Pharmacother. 2017;18:599–609.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52:243–252.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Katz IR, Reynolds CF 3rd. Carpenter D, Docherty JP, Ross RW. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7:361–376.
   PubMedGoogle Scholar
• Canadian Coalition for Senior’s Mental Health. National guidelines for seniors’ mental health – the assessment and treatment of depression. 2006. [updated 2018 Mar]. Available from: http://ccsmh.ca/ccsmh-national-guidelines-for-seniors-mental-health/
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, AsbergM A. new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–284.
   PubMed Web of Science ®Google Scholar
• Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. Bmj. 2012;344:e1566.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Del Campo L, Steinberg M, et al. Treating depression in alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–746.
   PubMed Web of Science ®Google Scholar
• Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with alzheimer’s disease. Int Psychogeriatr. 2001;13:233–240.
   PubMed Web of Science ®Google Scholar
• Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894–901.
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. CitAD research group. effect of citalopram on agitation in alzheimer disease: the citad randomized clinical trial. Jama. 2014;311:682–691.
   PubMed Web of Science ®Google Scholar
• Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in alzheimer’s dementia: evidence from the citad study. Am J Psychiatry. 2016;173:473–480.
   PubMed Web of Science ®Google Scholar
• Drye LT, Spragg D, Devanand DP, et al. Citad research group. changes in QTc interval in the citalopram for agitation in alzheimer’s disease (CitAD) randomized trial. PLoS One. 2014;9:e98426.
   PubMed Web of Science ®Google Scholar
• Petracca G, Tesón A, Chemerinski E, et al. A double-blind placebo-controlled study of clomipramine in depressed patients with alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1996;8:270–275.
   PubMed Web of Science ®Google Scholar
• Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in alzheimer’s disease patients with and without depression. Am J Psychiatry. 1989;146:45–49.
   PubMed Web of Science ®Google Scholar
• Wilkins JM, Forester BP. Update on SSRI treatment for neuropsychiatric symptoms of dementia. Curr Psychiatry Rep. 2016;18:14.
   PubMed Web of Science ®Google Scholar
• Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in alzheimer’s disease: A metaanalysis. Can J Psychiatry. 2007;52:248–255.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577–585.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378:403–411.
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136–145.
   PubMed Web of Science ®Google Scholar
• Martin BK, Frangakis CE, Rosenberg PB, et al. Design of depression in alzheimer’s disease study-2. Am J Geriatr Psychiatry. 2006;14:920–930.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332–340.
   PubMed Web of Science ®Google Scholar
• Drye LT, Martin BK, Frangakis CE, et al. Diads-2 research group do treatment effects vary among differing baseline depression criteria in depression in alzheimer’s disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011;26:573–583.
   PubMed Web of Science ®Google Scholar
• Flynn Longmire CV, Drye LT, Frangakis CE, et al. Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? Depression in alzheimer’s disease study 2. Am J Geriatr Psychiatry. 2014;22:14–24.
   PubMed Web of Science ®Google Scholar
• Munro CA, Longmire CF, Drye LT, et al. Cognitive outcomes after sertraline treatment in patients with depression of alzheimer disease. Am J Geriatr Psychiatry. 2012;20:1036–1044.
   PubMed Web of Science ®Google Scholar
• Sepehry AA, Lee PE, Hsiung GYR, et al. Effect of selective serotonin reuptake inhibitors in alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29:793–806.
   PubMed Web of Science ®Google Scholar
• Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage alzheimer’s disease. Am J Geriatr Psychiatry. 2000;8:66–74.
   PubMed Web of Science ®Google Scholar
• Romeo R, Knapp M, Hellier J, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry. 2013;202:121–128.
   PubMed Web of Science ®Google Scholar
• Holm KJ, Jarvis B, Foster RH. Mirtazapine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2000;17:515–534.
   PubMed Web of Science ®Google Scholar
• De Vasconcelos Cunha UG, Lopes Rocha F, Avi La De Melo R, et al. A placebo controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord. 2007;1:36–41.
   Web of Science ®Google Scholar
• Venlafaxine for Depression in Alzheimer’s DIsease (DIADs-3). 2012. [cited 2018 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT01609348.
   Google Scholar
• Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29:254–263.
   PubMedGoogle Scholar
• Rao V, Spiro JR, Rosenberg PB, et al. An open-label study of escitalopram (lexapro) for the treatment of ‘depression of alzheimer’s disease’ (dAD). Int J Geriatr Psychiatry. 2006;21:273–274.
   PubMed Web of Science ®Google Scholar
• Rabheru K Escitalopram and Depression in Elderly Alzheimer’s Patients. 2010. [cited 2018 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT00488670.
   Google Scholar
• Sverdlik A Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia. 2005. [cited 2018 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT00229333.
   Google Scholar
• An H, Choi B, Park KW, et al. The effect of escitalopram on mood and cognition in depressive alzheimer’s disease subjects. J Alzheimers Dis. 2017;55:727–735.
   PubMed Web of Science ®Google Scholar
• Mokhber N, Abdollahian E, Soltanifar A, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 2014;47:131–140.
   PubMed Web of Science ®Google Scholar
• Orgeta V, Tabet N, Nilforooshan R, et al. Efficacy of antidepressants for depression in alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58:725–733.
   PubMed Web of Science ®Google Scholar
• Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry. 1996;168:149–157.
   PubMed Web of Science ®Google Scholar
• Teri L, Reifler BV, Veith RC, et al. Imipramine in the treatment of depressed alzheimer’s patients: impact on cognition. J Gerontol. 1991;46:P372–7.
   PubMedGoogle Scholar
• Fuchs A, Hehnke U, Erhart C, et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry. 1993;26:37–41.
   PubMed Web of Science ®Google Scholar
• Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric syndromes professional interest area of istaart. neuropsychiatric symptoms in alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9:602–608.
   PubMed Web of Science ®Google Scholar
• Calhoun A, Ko J, Grossberg GT. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of alzheimer’s disease. Expert Opin Emerg Drugs. 2017;22:101–105.
   PubMed Web of Science ®Google Scholar
• Zajdel P, Marciniec K, Satała G, et al. N1-azinylsulfonyl-1H-indoles: 5-HT6 receptor antagonists with procognitive and antidepressant-like properties. ACS Med Chem Lett. 2016;7:618–622.
   PubMed Web of Science ®Google Scholar
• Wesołowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 2007;52:1274–1283.
   PubMed Web of Science ®Google Scholar
• Hirano K, Piers TM, Searle KL, et al. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer’s disease. Life Sci. 2009;84:558–562.
   PubMed Web of Science ®Google Scholar
• Lee K, Goodman L, Fourie C, et al. AMPA receptors as therapeutic targets for neurological disorders. Adv Protein Chem Struct Biol. 2016;103:203–261.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer’s Disease at Mild to Moderate Stages With Depressive Symptoms. [cited 2018 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT02626572
   Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27:215–223.
   PubMed Web of Science ®Google Scholar
• Butters MA, Whyte E, Nebes RD, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61:587–595.
   PubMed Web of Science ®Google Scholar
• Requena C, Lopez Ibor MI, Maestu F, et al. Effects of cholinergic drugs and cognitive training on dementia. Dement Geriatr Cogn Disord. 2004;18:50–54.
   PubMed Web of Science ®Google Scholar
• Rozzini L, Chilovi BV, Conti M, et al. Efficacy of SSRIS on cognition of alzheimer’s disease patients treated with cholinesterase inhibitors. Int Psychogeriatr. 2010;22:114–119.
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Rm A, et al. bava depression and alzheimer’s disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 2002;17:338–344.
   PubMedGoogle Scholar
• Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9–18.
   PubMed Web of Science ®Google Scholar
• Mowla A, Mosavinasab M, Haghshenas H, et al. Does serotonin augmentation have any effect on cognition and activities of daily living in alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27:484–487.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, et al. Donepezil MSAD, study investigators, group. efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14:389–404.
   PubMed Web of Science ®Google Scholar
• Carrasco MM, Agüera L, Gil P, et al. Safety and effectiveness of donepezil on behavioral symptoms in patients with alzheimer’s disease. Alzheimer Dis Assoc Disord. 2011;25:333–340.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Namiki C, Thuy DH, et al. Prediction of psychiatric response to donepezil in patients with mild to moderate alzheimer’s disease. J Neurol Sci. 2004;225:135–141.
   PubMed Web of Science ®Google Scholar
• Cummings JL, McRae T, Zhang R. Donepezil-sertraline study, group. effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605–612.
   PubMed Web of Science ®Google Scholar
• Spalletta G, Gianni W, Giubilei F, et al. Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month open-label observational study. Alzheimer Dis Assoc Disord. 2013;27:289–291.
   PubMed Web of Science ®Google Scholar
• Frankfort SV, Appels BA, De Boer A, et al. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in alzheimer’s disease in an outpatient geriatric setting. Int J Clin Pract. 2006;60:646–654.
   PubMed Web of Science ®Google Scholar
• Zheng-Fischhofer Q, Biernat J, Mandelkow EM, et al. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem. 1998;3:542–552.
   Google Scholar
• Hampel H, Ewers M, Burger K, et al. Lithium trial in alzheimer’s disease: A randomized, single blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70:922–931.
   PubMed Web of Science ®Google Scholar
• Del Ser T, Steinwachs KC, Gertz HJ, et al. Treatment of alzheimer’s disease with the GSK- 3 inhibitor tideglusib: A pilot study. J Alzheimers Dis. 2013;33:205–215.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.
   PubMed Web of Science ®Google Scholar
• Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:537–550.
   PubMed Web of Science ®Google Scholar
• Pr P, Kp P, Sy L, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: A double-blind, randomized, placebo-controlled trial. Am J Psychiatry. 2018;175:159–168.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate alzheimer disease: preliminary results. Arch Neurol. 2005;62:753–757.
   PubMed Web of Science ®Google Scholar
• Sjögren M, Hesse C, Basun H, et al. Tacrine and rate of progression in alzheimer’s disease–relation to apoe allele genotype. J Neural Transm (Vienna). 2001;108:451–458.
   PubMed Web of Science ®Google Scholar
• Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology. 2000;54:2061–2066.
   PubMed Web of Science ®Google Scholar
• Valen-Sendstad A, Engedal K, Stray-Pedersen B, et al. Effects of hormone therapy on depressive symptoms and cognitive functions in women with alzheimer disease: A 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry. 2010;18:11–20.
   PubMed Web of Science ®Google Scholar
• Seripa D, Franceschi M, Matera MG, et al. Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy. J Gerontol A Biol Sci Med Sci. 2006;61:918–923.
   PubMed Web of Science ®Google Scholar
• Ban TA, Morey L, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:525–551.
   PubMed Web of Science ®Google Scholar
• Loeb MB, Molloy DW, Smieja M, et al. A randomized, controlled trial of doxycycline and rifampin for patients with alzheimer’s disease. J Am Geriatr Soc. 2004;52:381–387.
   PubMed Web of Science ®Google Scholar
• Dw M, Ti S, Zhou Q, et al. Study DARAD group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of alzheimer’s disease: the Darad trial. Int J Geriatr Psychiatry. 2013;28:463–470.
   PubMed Web of Science ®Google Scholar
• Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid s-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet. 1991;338:1550–1554.
   PubMed Web of Science ®Google Scholar
• Hyland K, Smith I, Bottiglieri T, et al. Demyelination and decreased s-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency. Neurology. 1988;38:459–462.
   PubMed Web of Science ®Google Scholar
• Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid s-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral s-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096–1098.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Molecular pathology and pharmacogenomics in alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol. 2007;29(Suppl A):1–91.
   PubMedGoogle Scholar
• Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 1):28–47.
   PubMed Web of Science ®Google Scholar
• Lozupone M, Panza F, Stella E, et al. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? Expert Opin Drug Metab Toxicol. 2017;13:259–277.
   PubMed Web of Science ®Google Scholar
• Hendricksen M, Thomas AJ, Ferrier IN, et al. Neuropathological study of the dorsal raphe nuclei in late-life depression and alzheimer’s disease with and without depression. Am J Psychiatry. 2004;161:1096–1102.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486.
   PubMed Web of Science ®Google Scholar
• Willard HW. Organization, variation and expression of the human genome as a foundation of genomic and personalized medicine. In: Willard HW, Ginsburg GS, editors. Genomic and personalized medicine. London UK: Academic Press; 2009. p. 4–21.
   Google Scholar
• Lozupone M, Seripa D, Stella E, et al. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Rev Proteomics. 2017;14:809–824.
   PubMed Web of Science ®Google Scholar
• Ismail Z, Smith EE, Geda Y, et al. Istaart neuropsychiatric symptoms professional interest area. neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195–202.
   PubMed Web of Science ®Google Scholar
• Donovan NJ, Locascio JJ, Marshall GA, et al. Harvard Aging Brain Study. Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;appiajp201717040442. Epub ahead of print.
   Web of Science ®Google Scholar
• Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology. 2018;90:126–135.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Colenda CC, Beck C, et al. Task force of american association for geriatric psychiatry. position statement of the american association for geriatric psychiatry regarding principles of care for patients with dementia resulting from alzheimer disease. Am J Geriatr Psychiatry. 2006;14:561–572.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in alzheimer’s disease. Int Psychogeriatr. 2010;22:346–372.
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–769.
   PubMed Web of Science ®Google Scholar
• Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. Jama. 2012;308:2020–2029.
   PubMed Web of Science ®Google Scholar
• Jukić MM, Haslemo T, Molden E, et al. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients. Am J Psychiatry. 2018;appiajp201717050550. Epub ahead of print.
   Web of Science ®Google Scholar
• Bijl MJ, Luijendijk HJ, Van Den Berg JF, et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics. 2009;10:541–547.
   PubMed Web of Science ®Google Scholar
• Paroni G, Seripa D, Fontana A, et al. Klotho gene and selective serotonin reuptake inhibitors: response to treatment in late-life major depressive disorder. Mol Neurobiol. 2017;54:1340–1351.
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Seripa D, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset alzheimer’s disease. Ageing Res Rev. 2012;11:87–103.
   PubMed Web of Science ®Google Scholar
• Peters ME, Vaidya V, Drye LT, et al. DIADS-2 research, group. sertraline for the treatment of depression in alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011;24:222–228.
   PubMed Web of Science ®Google Scholar